The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Stefan A. Laufer

Pharmazeutisches Institut

Eberhard Karls Universität Tübingen

Tübingen

Germany

[email]@uni-tuebingen.de

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Pharmazeutisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany. 2010
  • Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Eberhard Karls University of Tübingen, Auf der Morgenstelle 8, Germany. 2002 - 2010
  • Institute of Pharmacy, University of Tuebingen, Auf der Morgenstelle 8b, DE-72076 Tuebingen, Germany. 2003 - 2004
  • Institute of Pharmacy, University of Tuebingen, Germany. 2003

References

  1. Different methods for testing potential cyclooxygenase-1 and cyclooxygenase-2 inhibitors. Laufer, S., Luik, S. Methods Mol. Biol. (2010) [Pubmed]
  2. Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors. Laufer, S., Hauser, D., Stegmiller, T., Bracht, C., Ruff, K., Schattel, V., Albrecht, W., Koch, P. Bioorg. Med. Chem. Lett. (2010) [Pubmed]
  3. Isoxazolone based inhibitors of p38 MAP kinases. Laufer, S.A., Margutti, S. J. Med. Chem. (2008) [Pubmed]
  4. Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity. Laufer, S., Koch, P. Org. Biomol. Chem. (2008) [Pubmed]
  5. Human whole blood assay for rapid and routine testing of non-steroidal anti-inflammatory drugs (NSAIDs) on cyclo-oxygenase-2 activity. Laufer, S., Greim, C., Luik, S., Ayoub, S.S., Dehner, F. Inflammopharmacology (2008) [Pubmed]
  6. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region. Laufer, S.A., Hauser, D.R., Domeyer, D.M., Kinkel, K., Liedtke, A.J. J. Med. Chem. (2008) [Pubmed]
  7. Substituted isoxazoles as potent inhibitors of p38 MAP kinase. Laufer, S.A., Margutti, S., Fritz, M.D. ChemMedChem (2006) [Pubmed]
  8. Development of a microsphere-based p38alpha kinase no-wash assay. Laufer, S., Linsenmaier, S. J. Biomol. Screen (2006) [Pubmed]
  9. Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: novel p38 MAP kinase inhibitors. Laufer, S.A., Ahrens, G.M., Karcher, S.C., Hering, J.S., Niess, R. J. Med. Chem. (2006) [Pubmed]
  10. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. Laufer, S.A., Domeyer, D.M., Scior, T.R., Albrecht, W., Hauser, D.R. J. Med. Chem. (2005) [Pubmed]
  11. An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays. Laufer, S., Thuma, S., Peifer, C., Greim, C., Herweh, Y., Albrecht, A., Dehner, F. Anal. Biochem. (2005) [Pubmed]
  12. Osteoarthritis therapy--are there still unmet needs?. Laufer, S. Rheumatology. (Oxford) (2004) [Pubmed]
  13. Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position. Laufer, S.A., Zimmermann, W., Ruff, K.J. J. Med. Chem. (2004) [Pubmed]
  14. International Conference on Inflammopharmacology -- VIII Side-Effects of Anti-inflammatory Drugs Symposium. Laufer, S. Expert. Opin. Investig. Drugs (2003) [Pubmed]
  15. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. Laufer, S.A., Wagner, G.K., Kotschenreuther, D.A., Albrecht, W. J. Med. Chem. (2003) [Pubmed]
  16. Role of eicosanoids in structural degradation in osteoarthritis. Laufer, S. Curr. Opin. Rheumatol (2003) [Pubmed]
  17. From imidazoles to pyrimidines: new inhibitors of cytokine release. Laufer, S.A., Wagner, G.K. J. Med. Chem. (2002) [Pubmed]
  18. Ones, thiones, and N-oxides: an exercise in imidazole chemistry. Laufer, S., Wagner, G., Kotschenreuther, D. Angew. Chem. Int. Ed. Engl. (2002) [Pubmed]
  19. Imidazole inhibitors of cytokine release: probing substituents in the 2 position. Laufer, S.A., Striegel, H.G., Wagner, G.K. J. Med. Chem. (2002) [Pubmed]
  20. An in-vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: a useful tool for the development of new antiarthritic and disease modifying drugs. Laufer, S., Greim, C., Bertsche, T. Osteoarthr. Cartil. (2002) [Pubmed]
 
WikiGenes - Universities